Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.
Chris Parker
Consultant or Advisory Role - Algeta (U)
Honoraria - Bayer
Daniel Heinrich
Consultant or Advisory Role - Algeta
Joe M. O'Sullivan
No relevant relationships to disclose
Sophie D. Fossa
Consultant or Advisory Role - Bristol-Myers Squibb; Sanofi
Honoraria - Amgen; Sanofi
Expert Testimony - Amgen; Sanofi
Ales Chodacki
No relevant relationships to disclose
Tomasz Demkow
No relevant relationships to disclose
John P. Logue
No relevant relationships to disclose
Mihalj Seke
No relevant relationships to disclose
Anders Widmark
No relevant relationships to disclose
Dag Clement Johannessen
No relevant relationships to disclose
Sten Nilsson
Consultant or Advisory Role - Algeta; Algeta
Honoraria - Algeta
Peter Hoskin
Research Funding - Algeta
Arne Solberg
No relevant relationships to disclose
Nicholas David James
Consultant or Advisory Role - Algeta
Research Funding - Algeta
Isabel Syndikus
No relevant relationships to disclose
Andrew Cross
No relevant relationships to disclose
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Jose E. Garcia-Vargas
Employment or Leadership Position - Bayer
A. Oliver Sartor
Consultant or Advisory Role - Algeta